|View printer-friendly version|
|September 19, 2007 1:57 p.m.|
|Teva Provides Update On Edratide For Systemic Lupus Erythematosus|
Jerusalem, Israel, September 19, 2007 - Jerusalem, Israel, September 19, 2007 Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company's synthetic peptide, edratide (TV-4710), did not meet its primary endpoint in the PRELUDE trial, a Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE). The drug candidate, administered as a subcutaneous weekly injection, was shown to be safe and well-tolerated.